Kaposi's sarcoma in HIV infection treated with vincristine and bleomycin.
OBJECTIVE
To evaluate the efficacy and toxicity of vincristine and bleomycin when used in combination to treat patients with progressive Kaposi's sarcoma.


METHODS
A retrospective case notes review.


METHODS
The departments of Immunology and Genito-Urinary Medicine, St Mary's Hospital, London, UK.


METHODS
All patients presenting with progressive Kaposi's sarcoma and requiring chemotherapy between January 1987 and January 1990, who had received no previous systemic chemotherapy.


METHODS
Treatment with vincristine (2 mg) and bleomycin (30 mg, 18 h infusion), or vinblastine (2.5-5.0 mg) if peripheral neuropathy developed. Treatment with zidovudine and prophylaxis of opportunistic infections where indicated.


METHODS
Response, toxicity and survival.


RESULTS
Overall, patients had a poor prognosis: 33 out of 46 (72%) had had a previous opportunistic infection, had a mean CD4 count of 144 x 10(6) (20 out of 46 tested) and a mean Karnofsky index of 75.4. They received a median of five cycles of therapy: a partial response was achieved in twenty-six patients (57%), disease progression was halted in a further 16 (35%), while disease progression continued in four (9%) despite therapy; there were no complete responders. Mean duration of response was 2 months (s.d., 1.26 months), survival was 8 months (s.d., 6.7 months) from start of therapy and 17 months (s.d., 8.9. months) from first AIDS diagnosis. On multivariate analysis the best predictor of mortality was the presence of previous opportunistic infection (P = 0.00653). Side-effects were minimal in comparison with other studies. The most common side-effect, in 13 cases (28%), was peripheral neuropathy, which may in part represent the prevalence of HIV neuropathy or remain as background. Haematological toxicity was uncommon.


CONCLUSIONS
Treatment for HIV-related Kaposi's sarcoma in advanced HIV disease is becoming more necessary as disease profiles change. Conventional chemotherapy regimens for malignancy are not well tolerated in these patients and may not be indicated. This regimen is effective and has low toxicity in AIDS patients. Non-responders should be considered for more intensive regimens.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D001761:Bleomycin / Q000627:therapeutic use* / Q000633:toxicity; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use* / Q000633:toxicity; D014750:Vincristine / Q000627:therapeutic use* / Q000633:toxicity
D001761:Bleomycin; D014750:Vincristine; D014747:Vinblastine